早期弥漫性皮肤型系统性硬化症自身抗体与器官受累的关联:PRESS 前瞻性注册研究
PRESS 前瞻性注册研究纳入 233 例病程不超过 2 年的弥漫性皮肤型系统性硬化症患者,比较抗 RNA 聚合酶 III 抗体阳性、抗拓扑异构酶 I 抗体阳性及双阴性三组的器官受累差异。结果显示抗拓扑异构酶 I 抗体阳性者基线肺功能更差且间质性肺病更常见,抗 RNA 聚合酶 III 抗体阳性者基线 mRSS 更高且硬皮病肾危象更常见;仅双阴性组肺功能随时间改善。
要点
- 抗拓扑异构酶 I 抗体阳性者基线 FVC% 预测值更低、间质性肺病更常见。
- 抗 RNA 聚合酶 III 抗体阳性者基线 mRSS 更高、硬皮病肾危象更常见。
- 仅双阴性组肺功能随时间改善,抗体分型在早期即有器官受累差异。
核心结论
- 早期弥漫性皮肤型系统性硬化症患者中,不同自身抗体亚型在基线即表现出器官受累差异。
- 仅双阴性组在随访中显示肺功能(FVC% 预测值)随时间改善。
研究设计与样本
- 前瞻性注册研究 PRESS,纳入 12 家美国学术中心、病程不超过 2 年且符合 2013 ACR/EULAR 分类标准的成人弥漫性皮肤型系统性硬化症患者。
- 共 303 例入组,233 例纳入分析(抗 RNA 聚合酶 III 抗体阳性 108 例、抗拓扑异构酶 I 抗体阳性 68 例、双阴性 57 例),每 6 个月评估一次。
- 排除双抗体阳性者,采用相应参数与非参数检验比较抗体组间差异。
主要发现
- 抗拓扑异构酶 I 抗体阳性组基线 FVC% 预测值低于抗 RNA 聚合酶 III 抗体阳性组(76.0% 对 86.0%,p=0.0011)。
- 抗拓扑异构酶 I 抗体阳性组间质性肺病患病率高于抗 RNA 聚合酶 III 抗体阳性组(69.6% 对 44.3%,p=0.0029)。
- 抗 RNA 聚合酶 III 抗体阳性组基线 mRSS 高于抗拓扑异构酶 I 抗体阳性组(25.0 对 17.9,p<0.0001)。
- 抗 RNA 聚合酶 III 抗体阳性组硬皮病肾危象患病率高于抗拓扑异构酶 I 抗体阳性组(14.4% 对 0.0%,p=0.0024)。
- 仅双阴性组 FVC% 预测值随时间改善(每年 +1.39%,p=0.03)。
关键数值与推荐
- 纳入标准为符合 2013 ACR/EULAR 系统性硬化症分类标准且病程不超过 2 年(自首个非雷诺现象症状起)的弥漫性皮肤型患者。
- 双抗体阳性者被排除。
- 自身抗体分组为抗 RNA 聚合酶 III 抗体阳性、抗拓扑异构酶 I 抗体阳性及双阴性。
临床怎么用
- 对早期弥漫性皮肤型系统性硬化症患者应尽早检测抗 RNA 聚合酶 III 抗体与抗拓扑异构酶 I 抗体以辅助器官受累风险评估。
- 抗拓扑异构酶 I 抗体阳性者需重点关注基线肺功能与间质性肺病筛查。
- 抗 RNA 聚合酶 III 抗体阳性者需关注皮肤厚度评分及硬皮病肾危象风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Anti-RNA-polymerase-III (ARA) and anti-topoisomerase-I (ATA) autoantibodies are associated with diffuse cutaneous SSc (dcSSc). ARA is associated with rapidly progressive skin thickening, scleroderma renal crisis (SRC), and gastric antral vascular ectasia, while ATA is associated with severe interstitial lung disease (ILD). However, these associations were derived from heterogenous SSc cohorts. As SSc is now often diagnosed earlier, we aimed to ascertain whether these relationships hold true in early dcSSc and to examine autoantibody associations with organ involvement in early dcSSc. METHODS: The Prospective Registry of Early Systemic Sclerosis (PRESS) includes adults with dcSSc ≤2 years from the first non-Raynaud's phenomenon symptom who met 2013 ACR/EULAR classification criteria for SSc. Participants were enrolled at 12 U.S. academic centers and evaluated every 6 months. Those with dual-positivity were excluded. Differences across autoantibody groups were assessed using appropriate parametric and nonparametric tests. RESULTS: Of 303 enrolled, 233 participants were included (108 ARA+, 68 ATA+, 57 double-negative). Mean age was 51 years; 68% were female. Mean disease duration was 1.2 years. ATA+ participants had lower baseline FVC% predicted (76.0%vs 86.0% ARA+, p = 0.0011) and higher prevalence of ILD (69.6%vs 44.3% ARA+, p = 0.0029). ARA+ participants had higher baseline mRSS (25.0 vs 17.9 ATA+, p < 0.0001) and higher prevalence of SRC (14.4%vs 0.0% ATA+, p = 0.0024). Only the double-negative group had improvement in FVC% predicted over time (+1.39% per year, p = 0.03). CONCLUSIONS: Autoantibody-specific differences in organ involvement were evident early. The double-negative group uniquely showed improvement in lung function over time.
引用
- Agarwal A, Hassan D, Huang S, et al. Autoantibody associations in patients with early diffuse cutaneous systemic sclerosis: the prospective registry of early systemic sclerosis. Semin Arthritis Rheum. 2026. PMID: 42391705. doi:10.1016/j.semarthrit.2026.153037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。